Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of sebetralstat (KVD900) for on-demand treatment of hereditary angioedema attacks, with an adolescent pharmacokinetic subtrial
2023-505904-41-00Phase 3Completed
- Sponsor
- KalVista Pharmaceuticals
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, open-label trial of sebetralstat in hereditary angioedema type I (HAE-I) and Hereditary Angioedema Type 2 (HAE2) (2 arms), sponsored by KalVista Pharmaceuticals. Primary endpoints: Adverse events, Laboratory abnormalities and 1 more. Started Feb 2024; status: completed.
02
Drugs
sebetralstat
03
Conditions
hereditary angioedema type I (HAE-I)Hereditary Angioedema Type 2 (HAE2)
Beyond the preview
Go deeper on 2023-505904-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505904-41-00.